Getinge Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Getinge de 13.6% y 5.2% por año respectivamente. Se prevé que el BPA crezca en un 13% al año. Se espera que la rentabilidad financiera sea de 10.4% en 3 años.

Información clave

13.2%

Tasa de crecimiento de los beneficios

13.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	23.5%
Tasa de crecimiento de los ingresos	5.2%
Rentabilidad financiera futura	10.4%
Cobertura de analistas	Good
Última actualización	26 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Results: Getinge AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 25

The Getinge AB (publ) (STO:GETI B) Annual Results Are Out And Analysts Have Published New Forecasts

Mar 30

Analysts Are Updating Their Getinge AB (publ) (STO:GETI B) Estimates After Its Full-Year Results

Feb 04

Recent updates

Results: Getinge AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 25

Is Getinge AB (publ) (STO:GETI B) Trading At A 41% Discount?

Apr 15

The Getinge AB (publ) (STO:GETI B) Annual Results Are Out And Analysts Have Published New Forecasts

Mar 30

Getinge's (STO:GETI B) Upcoming Dividend Will Be Larger Than Last Year's

Mar 29

The Return Trends At Getinge (STO:GETI B) Look Promising

Mar 21

Analysts Are Updating Their Getinge AB (publ) (STO:GETI B) Estimates After Its Full-Year Results

Feb 04

There's Reason For Concern Over Getinge AB (publ)'s (STO:GETI B) Price

Jan 20

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Jan 05

Getinge AB (publ)'s (STO:GETI B) Intrinsic Value Is Potentially 42% Above Its Share Price

Dec 20

Returns On Capital Are Showing Encouraging Signs At Getinge (STO:GETI B)

Dec 05

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Oct 06

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 37% Undervaluation?

Sep 21

Getinge's (STO:GETI B) Returns On Capital Are Heading Higher

Sep 03

Is Getinge (STO:GETI B) A Risky Investment?

Jun 28

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 23% Undervaluation?

Jun 15

Investors Will Want Getinge's (STO:GETI B) Growth In ROCE To Persist

Jun 01

At kr252, Is Getinge AB (publ) (STO:GETI B) Worth Looking At Closely?

May 05

Getinge (STO:GETI B) Has Announced That It Will Be Increasing Its Dividend To SEK4.25

Apr 05

Slowing Rates Of Return At Getinge (STO:GETI B) Leave Little Room For Excitement

Feb 28

Previsiones de crecimiento de beneficios e ingresos

OM:GETI B - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	37,542	3,760	4,190	5,638	9
12/31/2025	35,849	3,309	3,724	5,106	10
12/31/2024	34,194	2,838	3,286	4,694	10
3/31/2024	32,199	2,285	3,263	4,633	N/A
12/31/2023	31,827	2,412	1,604	2,957	N/A
9/30/2023	30,423	2,251	1,320	2,654	N/A
6/30/2023	29,756	2,154	1,252	2,519	N/A
3/31/2023	29,251	2,543	1,105	2,293	N/A
12/31/2022	28,292	2,491	2,231	3,367	N/A
9/30/2022	27,781	2,707	2,835	3,916	N/A
6/30/2022	27,146	2,665	3,085	4,135	N/A
3/31/2022	27,062	2,860	4,188	5,173	N/A
12/31/2021	27,049	2,970	5,630	6,560	N/A
9/30/2021	27,900	3,292	6,585	7,533	N/A
6/30/2021	29,571	3,916	6,893	7,811	N/A
3/31/2021	29,955	3,612	7,021	7,988	N/A
12/31/2020	29,819	3,239	6,154	7,199	N/A
9/30/2020	29,478	3,050	5,218	6,336	N/A
6/30/2020	27,738	1,878	4,239	5,437	N/A
3/31/2020	27,044	1,487	3,461	4,690	N/A
12/31/2019	26,559	1,222	2,612	3,832	N/A
9/30/2019	25,951	1,030	1,595	2,836	N/A
6/30/2019	25,398	-632	1,811	3,082	N/A
3/31/2019	24,852	-654	1,259	2,592	N/A
12/31/2018	24,172	-967	1,123	2,503	N/A
9/30/2018	23,653	-727	1,425	2,899	N/A
6/30/2018	22,914	847	812	2,371	N/A
3/31/2018	22,552	676	614	2,193	N/A
12/31/2017	22,495	1,096	N/A	2,763	N/A
9/30/2017	17,061	596	N/A	3,466	N/A
6/30/2017	19,046	390	N/A	3,599	N/A
3/31/2017	20,604	701	N/A	3,839	N/A
12/31/2016	22,170	698	N/A	3,671	N/A
9/30/2016	29,650	1,203	N/A	3,372	N/A
6/30/2016	29,646	1,462	N/A	3,369	N/A
3/31/2016	29,900	1,410	N/A	3,504	N/A
12/31/2015	30,235	1,390	N/A	3,458	N/A
9/30/2015	29,303	1,429	N/A	3,366	N/A
6/30/2015	28,603	1,622	N/A	3,386	N/A
3/31/2015	27,749	1,850	N/A	3,689	N/A
12/31/2014	26,669	1,433	N/A	3,473	N/A
9/30/2014	25,843	1,672	N/A	3,491	N/A
6/30/2014	25,468	1,718	N/A	3,674	N/A
3/31/2014	25,157	1,776	N/A	3,616	N/A
12/31/2013	25,287	2,285	N/A	3,544	N/A
9/30/2013	25,345	2,105	N/A	3,593	N/A
6/30/2013	25,070	2,210	N/A	3,390	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (13.6% al año) de GETI B es superior a la tasa de ahorro (0.9%).

Beneficios vs. Mercado: Se prevé que los beneficios (12.7% al año) de GETI B crezcan menos que el mercado Swedish (13.2% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de GETI B crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (5.2% al año) de GETI B crezcan más rápidamente que los del mercado Swedish (1.5% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 5.2% al año) de GETI B crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de GETI B sea baja dentro de 3 años (10.4%).

Getinge Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Results: Getinge AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

The Getinge AB (publ) (STO:GETI B) Annual Results Are Out And Analysts Have Published New Forecasts

Analysts Are Updating Their Getinge AB (publ) (STO:GETI B) Estimates After Its Full-Year Results

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Price target increased by 8.4% to kr229

Price target increased by 7.0% to kr220

Recent updates

Results: Getinge AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Upcoming dividend of kr4.40 per share

Is Getinge AB (publ) (STO:GETI B) Trading At A 41% Discount?

The Getinge AB (publ) (STO:GETI B) Annual Results Are Out And Analysts Have Published New Forecasts

Getinge's (STO:GETI B) Upcoming Dividend Will Be Larger Than Last Year's

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

The Return Trends At Getinge (STO:GETI B) Look Promising

Dividend increased to kr4.40

Getinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Getinge AB (Publ) Proposes Dividend, Payable on April 29, 2024

Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3

Analysts Are Updating Their Getinge AB (publ) (STO:GETI B) Estimates After Its Full-Year Results

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Getinge Announces CFO Changes

There's Reason For Concern Over Getinge AB (publ)'s (STO:GETI B) Price

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Price target increased by 8.4% to kr229

Getinge AB (publ)'s (STO:GETI B) Intrinsic Value Is Potentially 42% Above Its Share Price

Returns On Capital Are Showing Encouraging Signs At Getinge (STO:GETI B)

Price target increased by 7.0% to kr220

Consensus EPS estimates increase by 23%

Third quarter 2023 earnings: Revenues exceed analyst expectations

Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 37% Undervaluation?

Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023

Getinge's (STO:GETI B) Returns On Capital Are Heading Higher

Second quarter 2023 earnings: Revenues exceed analyst expectations

Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite

Is Getinge (STO:GETI B) A Risky Investment?

Consensus EPS estimates fall by 13%

Investor sentiment deteriorates as stock falls 22%

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 23% Undervaluation?

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.

Investors Will Want Getinge's (STO:GETI B) Growth In ROCE To Persist

At kr252, Is Getinge AB (publ) (STO:GETI B) Worth Looking At Closely?

First quarter 2023 earnings: Revenues exceed analyst expectations

Now 22% undervalued

Upcoming dividend of kr4.25 per share at 1.6% yield

Getinge (STO:GETI B) Has Announced That It Will Be Increasing Its Dividend To SEK4.25

Slowing Rates Of Return At Getinge (STO:GETI B) Leave Little Room For Excitement

Is Getinge AB (publ) (STO:GETI B) Trading At A 42% Discount?

Getinge (STO:GETI B) Is Paying Out A Larger Dividend Than Last Year

Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023

Is Getinge (STO:GETI B) Using Too Much Debt?

Full year 2022 earnings: EPS misses analyst expectations

Getinge AB (Publ) Proposes Dividend

Price target decreased to kr249

When Should You Buy Getinge AB (publ) (STO:GETI B)?

Price target decreased to kr272

U.S. Food and Drug Administration Broadens the Consent Decree with Getinge and Includes Its Subsidiary Datascope

Are Investors Undervaluing Getinge AB (publ) (STO:GETI B) By 49%?

Third quarter 2022 earnings: Revenues in line with analyst expectations

Getinge AB (publ) Provides Sales Guidance for the Full Year 2022

Getinge AB (Publ) Announces Executive Changes

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Getinge AB (Publ) Appoints Joanna Engelke as New Executive Vice President Quality Compliance, Regulatory & Medical Affairs and Member of the Getinge Executive Team

Price target decreased to kr293

Getinge AB (Publ) Announces Medical Device Field Action of Hls Set Advanced Products

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Getinge Appoints Agneta Palmér as Executive Vice President Operational Services Member of the Getinge Executive Team

Price target decreased to kr344

Getinge AB (publ) to Report Q2, 2022 Results on Jul 19, 2022

Lena Hagman to Leave Getinge AB (publ) as Executive Vice President Quality Compliance, Regulatory & Medical Affairs

We Think Getinge (STO:GETI B) Can Stay On Top Of Its Debt

Price target decreased to kr386